We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Metagenomic Sequencing Proposed for Respiratory Tract Infection Detection

By LabMedica International staff writers
Posted on 13 Dec 2018
Print article
Image: The HiSeq 4000 Systems leverage innovative patterned flow cell technology to provide rapid, high-performance sequencing. Perform production-scale, high-throughput exome or transcriptome sequencing projects quickly and economically (Photo courtesy of Illumina).
Image: The HiSeq 4000 Systems leverage innovative patterned flow cell technology to provide rapid, high-performance sequencing. Perform production-scale, high-throughput exome or transcriptome sequencing projects quickly and economically (Photo courtesy of Illumina).
Lower respiratory tract infections (LRTIs) are the leading cause of infectious disease-related deaths worldwide yet remains challenging to diagnose because of limitations in existing microbiologic tests.

In critically ill patients, noninfectious respiratory syndromes that resemble LRTIs further complicate diagnosis and confound targeted treatment. A sequencing-based strategy has been developed for simultaneously assessing pathogen, microbiome, and host response features to potentially diagnose individuals with lower respiratory tract infections.

A multidisciplinary team of scientists at the University of California, San Francisco (CA, USA) performed a prospective observational study that evaluated 92 adults with acute respiratory failure requiring mechanical ventilation who were admitted to the University of California, San Francisco (UCSF) Moffitt–Long Hospital ICUs. Subjects were enrolled sequentially between July 25, 2013, and October 17, 2017, within the first 72 hours of intubation for respiratory failure.

During the period of study enrollment, subjects received standard of care microbiologic testing ordered by the treating clinicians. Respiratory testing from bronchial alveolar lavage (BAL), or mini-BAL included: bacterial and fungal stains and semi-quantitative cultures for AFB stains and cultures (n = 8); 12-target clinical multiplex polymerase chain reaction for influenza A/B, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human rhinovirus (HRV), adenovirus (ADV), and 23 parainfluenza viruses (PIV) 1–4. Other microbiologic testing included 89 blood culture; 87 urine culture; four serum cryptococcal antigen; one serum galactomannan; and serum β-d-glucan. RNA-seq and DNA-seq libraries underwent 125-nt paired-end Illumina sequencing on a HiSeq 4000.

The scientists used rules-based and logistic regression computational models aimed at assaying for lung pathogens based on the DNA and RNA features gleaned from the metagenomic data. They initially tested the algorithms on 20 patients with or without acute lower respiratory tract infections, who had relatively clear diagnoses from the outset. They subsequently validated the models using data for another two dozen individuals, where they could detect lower respiratory tract infections with nearly 96% accuracy before taking the approach forward to a larger group of patients.

The authors concluded that they had addressed the need for better lower respiratory tract infection diagnostics by developing a metagenomic next-generation sequencing-based method that integrates host response and unbiased microbe detection. They then evaluated the performance of this approach in a prospective cohort of critically ill patients with acute respiratory failure. From these data, they suggested that it is possible to bring together pathogen, microbiome diversity, and host gene expression metrics to identify LRTI-positive patients and differentiate them from critically ill controls with non-infectious acute respiratory illnesses. The study was published on November 27, 2018, in the journal Proceedings of the National Academy of Sciences.

Related Links:
University of California, San Francisco

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.